AntiAg Cancer Research Results

AntiAg, Antiplatelet aggregation: Click to Expand ⟱
Source:
Type:
Antiplatelet aggregation refers to the process by which platelets clump together to form a blood clot.
The plethora of evidence indicates that among multiple hemostasis components, platelets play major roles in cancer progression by providing surface and granular contents for several interactions as well as behaving like immune cells.On the other hand, there are suggestions that antiplatelet treatment may promote solid tumor development in a phenomenon described as “cancers follow bleeding.” The controversies around antiplatelet agents justify insight into the subject to establish what, if any, role platelet-directed therapy has in the continuum of anticancer management.
The interplay between antiplatelet aggregation and cancer is an area of active research, with potential implications for therapeutic strategies. Antiplatelet agents, such as aspirin, are being investigated for their role in cancer prevention and treatment, particularly in reducing metastasis and improving patient outcomes.
Scientific Papers found: Click to Expand⟱
6475- 1,8-Cin,    1,8-Cineole inhibits platelet-leukocyte aggregate formation by reducing P-selectin expression
- in-vitro, HNSCC, NA
*P-sel↓, Inflam↓, AntiTum↑, AntiAg↑,
2559- AL,    Effect of the Garlic Pill in comparison with Plavix on Platelet Aggregation and Bleeding Time
- Human, Nor, NA
AntiAg↑, COX2/PTGS2↓, cardioP↑,
2463- AL,    Garlic as an antithrombotic and antiplatelet aggregation agent
- Review, Nor, NA
AntiAg↑, other↑,
2640- Api,    Apigenin: A Promising Molecule for Cancer Prevention
- Review, Var, NA
chemoPv↑, ITGB4↓, TumCI↓, TumMeta↓, Akt↓, ERK↓, p‑JNK↓, *Inflam↓, *PKCδ↓, *MAPK↓, EGFR↓, CK2↓, TumCCA↑, CDK1↓, P53↓, P21↑, Bax:Bcl2↑, Cyt‑c↑, APAF1↑, Casp↑, cl‑PARP↑, VEGF↓, Hif1a↓, IGF-1↓, IGFBP3↑, E-cadherin↑, β-catenin/ZEB1↓, HSPs↓, Telomerase↓, FASN↓, MMPs↓, HER2/EBBR2↓, CK2↓, eff↑, AntiAg↑, eff↑, FAK↓, ROS↑, Bcl-2↓, Cyt‑c↑, cl‑Casp3↑, cl‑Casp7↑, cl‑Casp8↑, cl‑Casp9↑, cl‑IAP2/BIRC3↑, AR↓, PSA↓, p‑pRB↓, p‑GSK‐3β↓, CDK4↓, ChemoSen↑, Ca+2↑, cal2↑,
2461- ASA,    Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis
- Review, NA, NA
AntiAg↑, COX1↓, eff↑,
5415- ASA,    The Anti-Metastatic Role of Aspirin in Cancer: A Systematic Review
- Review, Var, NA
TumMeta↓, COX1↓, TXA2↓, AntiAg↑, EMT↓, TumCMig↓, TumCI↓, AMPK↑, cMyc↓, PGE2↓, Dose↑, RadioS↑, PD-L1↓, E-cadherin↑, EMT↓, Slug↓, Vim↓, Twist↓, MMP2↓, MMP9↓, other↑,
4988- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, NA
HMGCR↓, SREBP2↑, SREBP2↓, AntiAg↑,
4986- ATV,  Dipy,    The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer
- Review, Var, NA
HMG-CoA↓, AntiAg↑, eff↑, Apoptosis↑, selectivity↑, *toxicity↓, TumCG↓, PDE4↓, other↑,
4989- Dipy,    Dipyridamole
- Review, NA, NA
AntiAg↑,
2562- EGCG,    Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Placebo-Controlled Clinical Trial
- Trial, NA, NA
AntiAg↑, other↝,
2563- EGCG,    Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies
- Review, NA, NA
cardioP↑, ROS↑, AntiAg↑, eff↑, COX1↓,
2561- EGCG,  ASA,    Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
- ex-vivo, Nor, NA
AntiAg↑, eff↑, Half-Life↝, other∅,
7737- isoFl,    An updated review of dietary isoflavones: Nutrition, processing, bioavailability and impacts on human health
- Review, Nor, NA
*cardioP↑, Risk↓, *BMD↑, *eff↑, *antiOx↑, *lipid-P↓, *LDL↓, AntiThr↑, AntiAg↑, PSA↓, TumCCA↑, cognitive↑, memory↑,
1807- NarG,    A Systematic Review of the Preventive and Therapeutic Effects of Naringin Against Human Malignancies
- Review, NA, NA
AntiTum↑, TumCP↓, tumCV↓, TumCCA↑, Mcl-1↓, RAS↓, e-Raf↓, VEGF↓, AntiAg↑, MMP2↓, MMP9↓, TIMP2↑, TIMP1↑, p38↓, Wnt↓, β-catenin/ZEB1↑, Casp↑, P53↑, BAX↑, COX2/PTGS2↓, GLO-I↓, CYP1A1↑, lipid-P↓, p‑Akt↓, p‑mTOR↓, VCAM-1↓, P-gp/ABCB1↓, survivin↓, Bcl-2↓, ROS↑, ROS↑, MAPK↑, STAT3↓, chemoP↑,
2970- PL,    Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways
- in-vitro, AML, NA
AntiAg↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↓, mTOR↓, p38↑, Casp3↑,
2950- PL,    Overview of piperlongumine analogues and their therapeutic potential
- Review, Var, NA
AntiAg↑, neuroP↑, Inflam↓, NO↓, PGE2↓, MMP3↓, MMP13↓, TumCMig↓, TumCI↓, p38↑, JNK↑, NF-kB↑, ROS↑, FOXM1↓, TrxR1↓, GSH↓, Trx↓, cMyc↓, Casp3↑, Bcl-2↓, Mcl-1↓, STAT3↓, AR↓, DNAdam↑,
2565- RES,    https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06788.x
- in-vitro, NA, NA - in-vivo, NA, NA
AntiAg↑, TXA2↑, PKCδ↑, Dose↝,
2564- RES,    Effect of resveratrol on platelet aggregation by fibrinogen protection
- in-vitro, NA, NA
AntiAg↑, antiOx↓, COX2/PTGS2↓,

Showing Research Papers: 1 to 18 of 18

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 18

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   CYP1A1↑, 1,   GSH↓, 1,   lipid-P↓, 1,   ROS↑, 5,   Trx↓, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

e-Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 1,   cMyc↓, 2,   FASN↓, 1,   GLO-I↓, 1,   HMG-CoA↓, 1,   SREBP2↓, 1,   SREBP2↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   p‑Akt↓, 1,   APAF1↑, 1,   Apoptosis↑, 2,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 3,   Casp↑, 2,   Casp3↑, 2,   cl‑Casp3↑, 1,   cl‑Casp7↑, 1,   cl‑Casp8↑, 1,   cl‑Casp9↑, 1,   CK2↓, 2,   Cyt‑c↑, 2,   cl‑IAP2/BIRC3↑, 1,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↑, 1,   Mcl-1↓, 2,   p38↓, 1,   p38↑, 2,   survivin↓, 1,   Telomerase↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,   other↑, 3,   other↝, 1,   other∅, 1,   p‑pRB↓, 1,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSPs↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↓, 1,   P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK4↓, 1,   P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 2,   ERK↓, 1,   FOXM1↓, 1,   p‑GSK‐3β↓, 1,   HMGCR↓, 1,   IGF-1↓, 1,   IGFBP3↑, 1,   mTOR↓, 1,   p‑mTOR↓, 1,   PI3K↓, 1,   RAS↓, 1,   STAT3↓, 2,   TumCG↓, 2,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 18,   Ca+2↑, 1,   cal2↑, 1,   E-cadherin↑, 2,   FAK↓, 1,   ITGB4↓, 1,   MMP13↓, 1,   MMP2↓, 2,   MMP3↓, 1,   MMP9↓, 2,   MMPs↓, 1,   PKCδ↑, 1,   Slug↓, 1,   TIMP1↑, 1,   TIMP2↑, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 1,   TumMeta↓, 2,   Twist↓, 1,   VCAM-1↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   Hif1a↓, 1,   NO↓, 1,   TXA2↓, 1,   TXA2↑, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 3,   COX2/PTGS2↓, 3,   Inflam↓, 2,   NF-kB↑, 1,   PD-L1↓, 1,   PGE2↓, 2,   PSA↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↑, 1,   Dose↝, 1,   eff↑, 6,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   EGFR↓, 1,   FOXM1↓, 1,   HER2/EBBR2↓, 1,   PD-L1↓, 1,   PSA↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 2,   cardioP↑, 2,   chemoP↑, 1,   chemoPv↑, 1,   cognitive↑, 1,   memory↑, 1,   neuroP↑, 1,   PDE4↓, 1,   Risk↓, 1,  
Total Targets: 130

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

P-sel↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   lipid-P↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

LDL↓, 1,  

Cell Death(tgid=5) ⓘ

MAPK↓, 1,  

Migration(tgid=13) ⓘ

PKCδ↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BMD↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   toxicity↓, 1,  
Total Targets: 11

Scientific Paper Hit Count for: AntiAg, Antiplatelet aggregation
3 Aspirin
3 Dipyridamole
3 EGCG (Epigallocatechin Gallate)
2 Allicin (mainly Garlic)
2 Atorvastatin
2 Piperlongumine
2 Resveratrol
1 1,8-Cineole
1 Apigenin (mainly Parsley)
1 isoflavones
1 Naringin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:10  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page